Krystal Biotech Inc (KRYS)

Working capital turnover

Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Revenue US$ in thousands 296,569 55,764 498 — —
Total current assets US$ in thousands 742,045 587,909 383,779 442,267 275,058
Total current liabilities US$ in thousands 101,995 33,094 28,847 25,736 15,452
Working capital turnover 0.46 0.10 0.00 0.00 0.00

December 31, 2024 calculation

Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $296,569K ÷ ($742,045K – $101,995K)
= 0.46

Krystal Biotech Inc's working capital turnover has shown a significant improvement over the years, with the ratio increasing from 0.00 in December 31, 2020, to 0.46 by December 31, 2024. This implies that the company is utilizing its working capital more efficiently to generate sales. A working capital turnover ratio of 0.46 in December 31, 2024 indicates that the company is generating $0.46 in revenue for every dollar of working capital invested. This improvement suggests that Krystal Biotech Inc has become more effective in managing its working capital and converting it into sales, which is a positive indicator for the company's financial health and operational efficiency.